• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Monopar Therapeutics Inc. - Common Stock (NQ:MNPR)

    114.90 +0.44 (+0.38%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 354,197
    Open 115.19
    Bid (Size) 104.16 (100)
    Ask (Size) 179.36 (200)
    Prev. Close 114.46
    Today's Range 110.51 - 117.46
    52wk Range 29.18 - 124.82
    Shares Outstanding 14,157,941
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
    From Monopar Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    +74.1%
    +74.1%
    1 Month
    +11.2%
    +11.2%
    3 Month
    +87.3%
    +87.3%
    6 Month
    +101.3%
    +101.3%
    1 Year
    +266.6%
    +266.6%

    More News

    Read More
    News headline image
    Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
    Via Benzinga
    News headline image
    Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
    Via Benzinga
    News headline image
    CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗
    Via Benzinga
    News headline image
    Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout ↗
    Via Investor's Business Daily
    News headline image
    Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    This Hilton Worldwide Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Monopar Therapeutics Inc. - Common Stock publicly traded?
    Yes, Monopar Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Monopar Therapeutics Inc. - Common Stock trade on?
    Monopar Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Monopar Therapeutics Inc. - Common Stock?
    The ticker symbol for Monopar Therapeutics Inc. - Common Stock is MNPR on the Nasdaq Stock Market
    What is the current price of Monopar Therapeutics Inc. - Common Stock?
    The current price of Monopar Therapeutics Inc. - Common Stock is 114.90
    When was Monopar Therapeutics Inc. - Common Stock last traded?
    The last trade of Monopar Therapeutics Inc. - Common Stock was at 08/12/26 04:00 PM ET
    What is the market capitalization of Monopar Therapeutics Inc. - Common Stock?
    The market capitalization of Monopar Therapeutics Inc. - Common Stock is 1.63B
    How many shares of Monopar Therapeutics Inc. - Common Stock are outstanding?
    Monopar Therapeutics Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.